Takeda’s Eohilia to compete Sanofi’s Dupixent in eosinophilic esophagitis treatment

The recent groundbreaking approval of Takeda’s Eohilia for patients 11 and older by the US Food and Drug Administration (FDA) may change the current treatment landscape for eosinophilic esophagitis (EoE), with Eohilia now being the only competitor of Sanofi’s Dupixent, which was once the only approved therapy against EoE in the US.